Resonance Health Limited Stock price

Equities

RHT

AU000000RHT2

Advanced Medical Equipment & Technology

Market Closed - Australian S.E. 10:47:55 2024-03-27 pm EDT 5-day change 1st Jan Change
0.07 AUD +7.69% Intraday chart for Resonance Health Limited +11.11% +16.67%
Sales 2022 3.85M 2.51M Sales 2023 4.47M 2.91M Capitalization 19.37M 12.62M
Net income 2022 -1M -651K Net income 2023 - 0 EV / Sales 2022 5.01 x
Net cash position 2022 6.51M 4.24M Net cash position 2023 6.09M 3.97M EV / Sales 2023 2.97 x
P/E ratio 2022
-22.4 x
P/E ratio 2023
-24.7 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 57.48%
More Fundamentals * Assessed data
Dynamic Chart
1 day+7.69%
1 week+11.11%
Current month+27.27%
1 month+25.00%
3 months+18.64%
6 months-12.50%
Current year+16.67%
More quotes
1 week
0.07
Extreme 0.065
0.07
1 month
0.06
Extreme 0.055
0.07
Current year
0.05
Extreme 0.047
0.07
1 year
0.04
Extreme 0.037
0.09
3 years
0.04
Extreme 0.037
0.21
5 years
0.04
Extreme 0.037
0.33
10 years
0.01
Extreme 0.014
0.33
More quotes
Managers TitleAgeSince
Chief Executive Officer - 23-06-30
Chief Tech/Sci/R&D Officer - 21-11-23
Director/Board Member 48 17-03-31
Members of the board TitleAgeSince
Director/Board Member 48 17-03-31
Chairman - 07-10-03
Director/Board Member - 09-10-04
More insiders
Date Price Change Volume
24-03-28 0.07 +7.69% 213,827
24-03-25 0.065 -7.14% 143,036
24-03-22 0.07 +11.11% 95,762
24-03-21 0.063 0.00% 402
24-03-20 0.063 -10.00% 15,471

Delayed Quote Australian S.E., March 27, 2024 at 10:47 pm EDT

More quotes
Resonance Health Limited is an Australia-based MedTech company. The Company specializes in the development and delivery of non-invasive medical imaging software and services. The Company is engaged in the development and commercialization of software-as-medical-device (SaMD) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. Its portfolio includes Core Lab and artificial intelligence (AI) powered products to partner with clinicians and radiologists for diagnosis, and management of patients in a variety of clinical settings. Its core SaMD product is FerriScan, a non-invasive liver analysis technology used for the assessment of iron in the liver. The Company's other SaMDs include Cardiac T2, for the assessment of iron in the heart, and HepaFat-Scan for the assessment of fat in and around the liver. The Company also has several AI-assisted SaMDs, including FerriSmart, HepaFat-AI, and LiverSmart.
More about the company
  1. Stock
  2. Equities
  3. Stock Resonance Health Limited - Australian S.E.